

# Warren Casey

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/828405/publications.pdf>

Version: 2024-02-01

22  
papers

812  
citations

567281

15  
h-index

610901

24  
g-index

26  
all docs

26  
docs citations

26  
times ranked

1119  
citing authors

#	ARTICLE	IF	CITATIONS
1	Profiling of the Tox21 10K compound library for agonists and antagonists of the estrogen receptor alpha signaling pathway. <i>Scientific Reports</i> , 2014, 4, 5664.	3.3	167
2	An evaluation framework for new approach methodologies (NAMs) for human health safety assessment. <i>Regulatory Toxicology and Pharmacology</i> , 2020, 112, 104592.	2.7	108
3	Multivariate models for prediction of human skin sensitization hazard. <i>Journal of Applied Toxicology</i> , 2017, 37, 347-360.	2.8	58
4	Status of acute systemic toxicity testing requirements and data uses by U.S. regulatory agencies. <i>Regulatory Toxicology and Pharmacology</i> , 2018, 94, 183-196.	2.7	58
5	Advancing toxicology research using in vivo high throughput toxicology with small fish models. <i>ALTEX: Alternatives To Animal Experimentation</i> , 2016, 33, 435-452.	1.5	48
6	An integrated chemical environment with tools for chemical safety testing. <i>Toxicology in Vitro</i> , 2020, 67, 104916.	2.4	37
7	Reflections on the progress towards non-animal methods for acute toxicity testing of chemicals. <i>Regulatory Toxicology and Pharmacology</i> , 2019, 102, 30-33.	2.7	32
8	Validation of Alternative In Vitro Methods to Animal Testing: Concepts, Challenges, Processes and Tools. <i>Advances in Experimental Medicine and Biology</i> , 2016, 856, 65-132.	1.6	31
9	Identifying environmental chemicals as agonists of the androgen receptor by using a quantitative high-throughput screening platform. <i>Toxicology</i> , 2017, 385, 48-58.	4.2	24
10	Non-animal replacement methods for human vaccine potency testing: state of the science and future directions. <i>Procedia in Vaccinology</i> , 2011, 5, 16-32.	0.4	23
11	Recommendations toward a human pathway-based approach to disease research. <i>Drug Discovery Today</i> , 2018, 23, 1824-1832.	6.4	23
12	Opportunities for use of one species for longer-term toxicology testing during drug development: A cross-industry evaluation. <i>Regulatory Toxicology and Pharmacology</i> , 2020, 113, 104624.	2.7	22
13	Evaluation of Variability Across Rat Acute Oral Systemic Toxicity Studies. <i>Toxicological Sciences</i> , 2022, 188, 34-47.	3.1	22
14	Application of Reverse Dosimetry to Compare <i>In Vitro</i> and <i>In Vivo</i> Estrogen Receptor Activity. <i>Applied in Vitro Toxicology</i> , 2015, 1, 33-44.	1.1	19
15	International Harmonization and Cooperation in the Validation of Alternative Methods. <i>Advances in Experimental Medicine and Biology</i> , 2016, 856, 343-386.	1.6	16
16	United States regulatory requirements for skin and eye irritation testing. <i>Cutaneous and Ocular Toxicology</i> , 2019, 38, 141-155.	1.3	14
17	Rethinking chronic toxicity and carcinogenicity assessment for agrochemicals project (ReCAAP): A reporting framework to support a weight of evidence safety assessment without long-term rodent bioassays. <i>Regulatory Toxicology and Pharmacology</i> , 2022, 131, 105160.	2.7	13
18	Systems biology for organotypic cell cultures. <i>ALTEX: Alternatives To Animal Experimentation</i> , 2017, 34, 301-310.	1.5	10

#	ARTICLE	IF	CITATIONS
19	Assessing chemical carcinogenicity: hazard identification, classification, and risk assessment. Insight from a Toxicology Forum state-of-the-science workshop. <i>Critical Reviews in Toxicology</i> , 2021, 51, 653-694.	3.9	10
20	Validation of the OptiSafe <sup>®</sup> eye irritation test. <i>Cutaneous and Ocular Toxicology</i> , 2020, 39, 180-192.	1.3	6
21	Performance of the BG1Luc ER TA method in a qHTS format. <i>ALTEX: Alternatives To Animal Experimentation</i> , 2015, 32, 287-96.	1.5	4
22	Increasing the use of animal-free recombinant antibodies. <i>ALTEX: Alternatives To Animal Experimentation</i> , 2020, 37, 309-311.	1.5	4